Table 1. The medical history and baseline biochemical parameters of 307 coronary artery disease (CAD) patients with renal insufficiency.
| Medical history and medication | Number of cases (percentage) | Clinical parameter | Mean ± SD (median, interquartile range) |
| Medical history | - | SBP (mmHg) | 137±24 |
| Hypertension | 266(83%) | DBP (mmHg) | 76±13 |
| Diabetes | 103(32%) | Albumin(g/l) | 37±4 |
| Cerebrovascular disease | 134(42%) | Hemoglobulin(g/l) | 120±22 |
| Hyperuricemia | 209(65%) | Platelet (per ml) | 174±105 |
| Microalbuminuria | 160(50%) | LDL (mmol/l) | 2.1±0.8 |
| AMI | 116(38%) | Triglyceride(mmol/l) | 1.3±0.6 |
| PCI | 101(33%) | Cholesterol(mmol/l) | 3.9±1.0 |
| Atrial fibrillation | 133(43.3%) | Magnesium(mmol/l) | 0.8±0.2 |
| Doubling of serum creatinine | 96(31%) | Calcium(mmol/l) | 2.2±0.1 |
| Medication history | - | Phosphorus(mmol/l) | 1.2±0.2 |
| CCB | 202(66%) | Uric acid (μmol/l) | 483±135 |
| ACEI/ARBs | 98(32%) | eGFR(ml/min.1.73m2) | 46±14 |
| Diuretic drug | 162(53%) | NT-pro BNP (pg/ml) | 2848(816-8746) |
| Statins | 251(82%) | LVEF (%) | 55±10 |
| single anti-platelet agent | 123(40%) | ||
| dual anti-platelet agent | 122(40%) | ||
| Warfarin | 25(8.1%) | ||
| Rivaroxaban or Dabigatran | 8(2.6%) | ||
| Beta-receptor blocker | 168(55%) |
Note: CAD, Coronary artery disease; AMI, acute myocardial infarction; PCI, percutaneous coronary Intervention; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; CCB, calcium channel blocker; ACEI, Angiotensin-Converting Enzyme Inhibitors; ARB, Angiotensin Receptor Blockers; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; NT-pro BNP, Amino-terminal pro-B type natriuretic peptide.